Sign In
Buy NYXH
$2.87
-0.100 (-3.37%)
At Close: Jun 03, 2026
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
01:30pm, Tuesday, 07'th Oct 2025
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
01:00am, Monday, 06'th Oct 2025
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage
Publication relating to transparency notifications
04:30pm, Friday, 03'rd Oct 2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 Ma
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
10:11am, Thursday, 02'nd Oct 2025
NYXH expands in the Middle East after Abu Dhabi's first Genio implant, aiming to broaden access for OSA patients.
Nyxoah Provides an Update on Expanded Middle East Presence
04:10pm, Tuesday, 23'rd Sep 2025
Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – Sep
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
04:10pm, Monday, 15'th Sep 2025
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH
Nyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
02:50am, Wednesday, 10'th Sep 2025
Nyxoah SA (NASDAQ:NYXH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Olivier Taelman - CEO & Executive Director Presentation Unknown Anal
Publication relating to transparency notifications
04:30pm, Friday, 05'th Sep 2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 5, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2
Nyxoah Announces Upcoming Investor Events
04:30pm, Tuesday, 02'nd Sep 2025
Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”)
Nyxoah: High-Risk High-Reward Medtech To Own
08:00am, Wednesday, 20'th Aug 2025
Nyxoah's Genio system received FDA approval, unlocking access to the US market and validating its innovative, patient-friendly OSA treatment. Recent earnings show strong revenue growth but continued l
Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript
07:07pm, Monday, 18'th Aug 2025
Nyxoah SA (NASDAQ:NYXH ) Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO & Executive Director Pearson Denni
Nyxoah Reports Second Quarter Financial and Operating Results
04:10pm, Monday, 18'th Aug 2025
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
11:11am, Friday, 15'th Aug 2025
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
01:00am, Monday, 11'th Aug 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah�
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
04:10pm, Friday, 08'th Aug 2025
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert
